MIME-Version: 1.0 Server: WebSTAR/2.1 ID/32304 Message-ID: Date: Sun, 14 Dec 1997 19:50:14 GMT Last-Modified: Tue, 01 Jul 1997 00:14:56 GMT Content-type: text/html Content-length: 3406 Epix Medical Home Page


HomeAbout EPIXMS-325Technology R&DNews
PublicationsEmployment OpportunitiesInvestor InfoRequest Information


Company Overview

Based in Cambridge, Mass., EPIX Medical, Inc. (Nasdaq: EPIX) is developing targeted contrast agents to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The lead product under development, MS-325, is an injectable contrast agent designed for multiple vascular imaging indications, including coronary artery disease and peripheral vascular disease.

EPIX believes that MS-325 will significantly enhance image quality and provide physicians with a clinically superior, noninvasive and cost-effective method for diagnosing cardiovascular disease. MS-325 should also simplify the diagnosis for many diseases and in many cases replace highly invasive and expensive X-ray angiography -- currently considered the definitive diagnostic exam for cardiovascular disease.

An estimated 3.5 million X-ray angiograms are performed in the United States each year at an estimated cost to the health care system of over $6 billion. A growing worldwide problem, cardiovascular disease kills approximately one million people in the United States each year, making it the nation's leading cause of death.

Illustration showing MS-325 being injected into the blood stream and attaching to the protein albumin. MS-325 is designed to provide enhanced signals to an MRI scanner, thereby improving the quality of the images of the vasculature.


© 1997, EPIX Medical, Inc.

E-mail us at info@epixmed.com